Exhibit 99.1


 Sono-Tek Announces First Sale of MediSonic Batch Coating System for Thin Film
                Deposition in the Field of Diabetes Management.

(December 22, 2005 - MILTON, NY) Sono-Tek Corporation (OTC Bulletin Board: SOTK
- - News) announced today that it has sold the first MediSonic system for use in
the diabetes management field.

The MediSonic system is a patented polymer vacuum deposition process that
incorporates Sono-Tek's unique ultrasonic atomizing nozzle. The design allows
for batch process coating of small devices such as stents or other implantables,
which otherwise must be coated one at a time. Batch processing of such small
medical devices is highly desirable to increase throughput as well as
consistency from device to device. Sono-Tek originally developed the MediSonic
system for the purpose of stent coating, and this is the first venture into
batch coating of medical devices other than stents.

CEO and President of Sono-Tek, Dr. Christopher L. Coccio, stated "Our continued
development of the MediSonic system has shown promising coating consistency on
stents, and now has allowed us to venture into new areas, such as diabetes
management."

For further information, including our recent "Shareholder Letter",
http://www.sono-tek.com/images/_investors/PressRelease.pdf, which was released
December 21, 2005, contact Dr. Christopher L. Coccio, President and CEO at
845-795-2020, or visit our website at http://www.sono-tek.com

Sono-Tek Corporation is a leading developer and manufacturer of liquid spray
products based on its proprietary ultrasonic nozzle technology. Founded in 1975,
the Company's products have long been recognized for their performance, quality
and reliability.

This press release contains forward looking statements regarding future events
and the future performance of Sono-Tek Corporation that involve risks and
uncertainties that could cause actual results to differ materially. These
factors include, among other considerations, general economic and business
conditions; political, regulatory, competitive and technological developments
affecting the Company's operations or the demand for its products; timely
development and market acceptance of new products; adequacy of financing;
capacity additions and the ability to enforce patents. We refer you to documents
that the company files with the Securities and Exchange Commission, which
includes Form 10-KSB and Form 10-QSBs containing additional important
information.